QPPV.COM KNOWLEDGE ASSESSMENT

Risankizumab: Classification, History, Mechanism of Action, Safety and Pharmacovigilance

Test your understanding of the concepts covered by Risankizumab: Classification, History, Mechanism of Action, Safety and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Which control best supports traceability from an individual risankizumab case to broader pharmacovigilance action?

Maintaining separate, unlinked systems for cases, quality complaints and medical-information contacts Linking case data with quality complaints, medical-information contacts, distribution records and aggregate analyses Removing batch information after the case is medically reviewed Pooling all events without retaining source information

Question 2 of 10 Why is the IL-23 p19 target relevant to pharmacovigilance assessment?

It identifies the biological pathway whose modulation can support both therapeutic effects and plausible safety hypotheses It proves that every infection occurring during treatment is caused by risankizumab It eliminates the need to evaluate the patient's underlying inflammatory disease It determines the product batch and administration route used in a case

Question 3 of 10 A patient with inflammatory bowel disease develops liver injury while receiving risankizumab and another potentially hepatotoxic medicine. What is the most appropriate interpretation?

The presence of risankizumab makes the concomitant medicine irrelevant The event should be attributed to risankizumab because liver injury is a mechanism-led concern Both medicines and non-drug causes should be evaluated using serial tests, timing and competing-cause assessment Causality cannot be assessed unless the patient is rechallenged

Question 4 of 10 Which statement best reflects the relationship between risankizumab's mechanism and causality assessment?

A biologically plausible mechanism is sufficient to classify an event as treatment-related Mechanism is irrelevant once an event is listed in the product information Mechanism helps formulate and test a safety hypothesis but does not establish individual case causality Mechanism can establish causality only when the event is serious

Question 5 of 10 Which conclusion is most consistent with the article's definition of a safety signal?

A signal is definitive proof that the medicine caused the event A signal is a hypothesis requiring further evaluation against clinical, epidemiological and product-related evidence A signal exists only when every individual case is complete A signal can be established solely by a plausible biological mechanism

Question 6 of 10 Why are preferred-term counts alone insufficient for interpreting a risankizumab safety signal?

Preferred terms cannot ever be used in pharmacovigilance Several terms may represent one syndrome, while one term may combine different mechanisms, and counts lack clinical context Counts are sufficient if the event is serious Preferred-term counts automatically account for background disease rates

Question 7 of 10 Why should route and administration chronology be reconstructed precisely in a risankizumab case?

They are needed only to determine whether the patient had the correct indication They help distinguish administration reactions, handling issues and exposure timing, including different administration settings They replace the need to document the event phenotype They determine whether a reported event must be considered unrelated

Question 8 of 10 A case report describes fever two days after risankizumab administration. Which initial approach is most scientifically appropriate?

Code the event immediately as a drug-induced administration reaction Assume it represents loss of disease control because fever is not a local reaction Evaluate infection, inflammatory disease activity and administration-related reaction using chronology and objective findings Exclude the event from pharmacovigilance because fever is nonspecific

Question 9 of 10 Why should interruption of risankizumab not automatically be treated as complete dechallenge?

Biological medicines cannot have any pharmacodynamic effects after dosing stops Persistent pharmacodynamic activity may mean that biological reversal is not immediate, and other interventions may confound the outcome Dechallenge is relevant only for non-serious events Treatment interruption proves that the event was caused by the medicine

Question 10 of 10 Why should the indication be retained in both individual case review and aggregate analysis?

Indication is administrative information with no effect on medical interpretation Different diseases and treatment phases can have different background event rates, disease manifestations and benefit-risk considerations Indication determines causality without requiring other evidence All indications use identical schedules and patient populations

QPPV.com

Risankizumab: Classification, History, Mechanism of Action, Safety and Pharmacovigilance

Cookie Settings